In glioblastoma multiforme (GBM), promoter methylation and silencing of methyl-glutamyl methyltransferase (MGMT), a critically important resistance mechanism to standard-of-care temozolomide (TMZ) chemotherapy, occurs more frequently in female compared with male patients (43). This evidence concerns the gene MGMT and glioblastoma.